Market Overview

UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral with $46 PT

Related BMRN
UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside
FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

Wedbush maintained its Neutral rating and $46 price target on BioMarin Pharmaceuticals (NASDAQ: BMRN).

Wedbush noted, "We have made adjustments to our model projections based on clarity of GALNS approval timing, clarity on geographic distribution of Morquio patients, and initial 2013 R&D guidance of $340-$370 million. The company has already identified about 1,200 MPS IVA patients and they estimate there are about 3,000 patients worldwide, with about 20% in North America and 50% in Europe. Regulatory guidance included potential delays in approval timing due to changes in US and EU processes. We have updated our model with the net effect being that our peak sales estimate was reduced to about $649 million from about $745 million. In addition, our projected full-year profitability is delayed to 2016 from 2014."

BioMarin Pharmaceuticals closed at $47.86 on Thursday.

Latest Ratings for BMRN

DateFirmActionFromTo
Dec 2014JP MorganMaintainsOverweight
Dec 2014UBSMaintainsBuy
Nov 2014JefferiesMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional